Protagenic Therapeutics, Inc.
149 Fifth Avenue
New York, NY 10010
June 21, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Re: | Protagenic Therapeutics, Inc. Registration Statement on Form S-3 Filed June 21, 2021 File No. 333-256790 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned hereby requests that the Company’s Registration Statement on Form S-3 (File No. 333-256790) filed with the U.S. Securities and Exchange Commission (the “Commission”) on June 21, 2021 (the “Registration Statement”), be declared effective on June 23, 2021, at 9:00 a.m., Eastern Standard Time, or as soon as practicable thereafter.
| Very truly yours, | ||
| PROTAGENIC THERAPEUTICS, INC. | ||
| By: | /s/ Alexander K. Arrow | |
Alexander K. Arrow Chief Financial Officer | ||
cc: Dean Colucci, Duane Morris LLP
